- TCRR Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
Tcr2 Therapeutics (TCRR) 8-K14 Dec 20TCR2 Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid TumorsFinancial data
Company Profile